Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei CNCM I-1572 + vitamin D
- Development stage
- Unknown
- Lead developer
- SOFAR
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination of the probiotic bacterial strain *Lactobacillus paracasei* CNCM I-1572 (also known as *L. casei* DG) and vitamin D. Developed by SOFAR S.p.A., this combination is primarily investigated for its ability to enhance the absorption and systemic bioavailability of vitamin D in patients with vitamin D deficiency. The probiotic component modulates the gut microbiota and immune system, reducing intestinal inflammation and potentially improving the environment for nutrient absorption. Clinical and preclinical studies have demonstrated that co-administration of this specific probiotic strain with vitamin D3 supplements can significantly increase serum levels of 25-hydroxyvitamin D compared to vitamin D supplementation alone.
- Brand names
- Enterolactis
- Other names
- Lactobacillus casei DG + vitamin DL. casei DG + vitamin DLactobacillus paracasei CNCM I-1572 + vitamin D3
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on lactobacillus paracasei CNCM I-1572 + vitamin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei CNCM I-1572 + vitamin D.